Skip to main content
NCBI home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1994 Jan;7(1):14–28. doi: 10.1128/cmr.7.1.14

Markers predicting progression of human immunodeficiency virus-related disease.

C M Tsoukas 1, N F Bernard 1
PMCID: PMC358303  PMID: 8118788

Abstract

Human immunodeficiency virus (HIV) interacts with the immune system throughout the course of infection. For most of the disease process, HIV activates the immune system, and the degree of activation can be assessed by measuring serum levels of molecules such as beta 2-microglobulin and neopterin, as well as other serum and cell surface phenotype markers. The levels of some of these markers correlate with clinical progression of HIV disease, and these markers may be useful as surrogate markers for development of clinical AIDS. Because the likelihood and timing of development of clinical AIDS following seroconversion, for any particular individual, are not readily predictable, the use of nonclinical disease markers has become critically important to patient management. Surrogate markers of HIV infection are, by definition, measurable traits that correlate with disease progression. An ideal marker should identify patients at highest risk of disease progression, provide information on how long an individual has been infected, help in staging HIV disease, predict development of opportunistic infections associated with AIDS, monitor the therapeutic efficacy of immunomodulating or antiviral treatments, and the easily quantifiable, reliable, clinically available, and affordable. This review examines the current state of knowledge and the role of surrogate markers in the natural history and treatment of HIV infection. The clinical usefulness of each marker is assessed with respect to the criteria outlined for the ideal surrogate marker for HIV disease progression.

Full text

PDF
14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abita J. P., Cost H., Milstien S., Kaufman S., Saimot G. Urinary neopterin and biopterin levels in patients with AIDS and AIDS-related complex. Lancet. 1985 Jul 6;2(8445):51–52. doi: 10.1016/s0140-6736(85)90111-4. [DOI] [PubMed] [Google Scholar]
  2. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  3. Allain J. P., Laurian Y., Paul D. A., Verroust F., Leuther M., Gazengel C., Senn D., Larrieu M. J., Bosser C. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med. 1987 Oct 29;317(18):1114–1121. doi: 10.1056/NEJM198710293171804. [DOI] [PubMed] [Google Scholar]
  4. Amadori A., Chieco-Bianchi L. B-cell activation and HIV-1 infection: deeds and misdeeds. Immunol Today. 1990 Oct;11(10):374–379. doi: 10.1016/0167-5699(90)90144-x. [DOI] [PubMed] [Google Scholar]
  5. Anderson R. E., Lang W., Shiboski S., Royce R., Jewell N., Winkelstein W., Jr Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection. Arch Intern Med. 1990 Jan;150(1):73–77. [PubMed] [Google Scholar]
  6. Aucouturier P., Couderc L. J., Gouet D., Danon F., Gombert J., Matheron S., Saimot A. G., Clauvel J. P., Preud'homme J. L. Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome. Clin Exp Immunol. 1986 Jan;63(1):234–240. [PMC free article] [PubMed] [Google Scholar]
  7. Bahraoui E., Benjouad A., Sabatier J. M., Allain J. P., Laurian Y., Montagnier L., Gluckman J. C. Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection. Blood. 1990 Jul 1;76(1):257–264. [PubMed] [Google Scholar]
  8. Balkwill F. R., Burke F. The cytokine network. Immunol Today. 1989 Sep;10(9):299–304. doi: 10.1016/0167-5699(89)90085-6. [DOI] [PubMed] [Google Scholar]
  9. Bass H. Z., Hardy W. D., Mitsuyasu R. T., Taylor J. M., Wang Y. X., Fischl M. A., Spector S. A., Richman D. D., Fahey J. L. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. J Acquir Immune Defic Syndr. 1992;5(3):215–221. [PubMed] [Google Scholar]
  10. Bass H. Z., Nishanian P., Hardy W. D., Mitsuyasu R. T., Esmail E., Cumberland W., Fahey J. L. Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol. 1992 Jul;64(1):63–70. doi: 10.1016/0090-1229(92)90060-2. [DOI] [PubMed] [Google Scholar]
  11. Bethea M., Forman D. T. Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990 May-Jun;20(3):163–168. [PubMed] [Google Scholar]
  12. Blazquez M. V., Madueño J. A., Gonzalez R., Jurado R., Bachovchin W. W., Peña J., Muñoz E. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol. 1992 Nov 1;149(9):3073–3077. [PubMed] [Google Scholar]
  13. Bloom E. J., Abrams D. I., Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA. 1986 Jul 25;256(4):491–493. [PubMed] [Google Scholar]
  14. Breustedt W., Rabe H., Volk D., Porstmann P. Neopterin--ein prognostischer Marker bei der HIV-Infektion. Dermatol Monatsschr. 1989;175(4):226–231. [PubMed] [Google Scholar]
  15. Brew B. J., Bhalla R. B., Fleisher M., Paul M., Khan A., Schwartz M. K., Price R. W. Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. Neurology. 1989 Jun;39(6):830–834. doi: 10.1212/wnl.39.6.830. [DOI] [PubMed] [Google Scholar]
  16. Burkes R. L., Sherrod A. E., Stewart M. L., Gill P. S., Aguilar S., Taylor C. R., Krailo M. D., Levine A. M. Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy. Cancer. 1986 Jun 1;57(11):2190–2192. doi: 10.1002/1097-0142(19860601)57:11<2190::aid-cncr2820571118>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  17. Byar D. P., Schoenfeld D. A., Green S. B., Amato D. A., Davis R., De Gruttola V., Finkelstein D. M., Gatsonis C., Gelber R. D., Lagakos S. Design considerations for AIDS trials. N Engl J Med. 1990 Nov 8;323(19):1343–1348. doi: 10.1056/NEJM199011083231912. [DOI] [PubMed] [Google Scholar]
  18. Böttiger B., Blombäck M., Berntorp E., Egberg N., Nilsson I. M., Schulman S., Stigendal L., Biberfeld G. HIV-serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. Eur J Haematol. 1988 Nov;41(5):459–466. doi: 10.1111/j.1600-0609.1988.tb00228.x. [DOI] [PubMed] [Google Scholar]
  19. Böttiger B., Morfeldt-Månson L., Putkonen P., Nilsson B., Julander I., Biberfeld G. Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy. Scand J Infect Dis. 1989;21(5):507–514. doi: 10.3109/00365548909037878. [DOI] [PubMed] [Google Scholar]
  20. Calabrese L. H., Proffitt M. R., Gupta M. K., Easley K. A., Walker J. R., Rehm S. J., Valenzuela R., Clough J. D. Serum beta 2-microglobulin and interferon in homosexual males: relationship to clinical findings and serologic status to the human T lymphotropic virus (HTLV-III). AIDS Res. 1984;1(6):423–438. doi: 10.1089/aid.1.1983.1.423. [DOI] [PubMed] [Google Scholar]
  21. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1990. A 68-year-old man with a right hemiparesis, abulia, and multiple intracerebral hemorrhages. N Engl J Med. 1990 Jun 28;322(26):1866–1878. doi: 10.1056/NEJM199006283222608. [DOI] [PubMed] [Google Scholar]
  22. Cheingsong-Popov R., Panagiotidi C., Bowcock S., Aronstam A., Wadsworth J., Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ. 1991 Jan 5;302(6767):23–26. doi: 10.1136/bmj.302.6767.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Cheingsong-Popov R., Panagiotidi C., Caun K., Klasse P. J., Pipkorn R., Blomberg J., Weber J. Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583-599), do not correlate significantly with outcome in HIV infection. AIDS. 1990 Mar;4(3):251–253. doi: 10.1097/00002030-199003000-00012. [DOI] [PubMed] [Google Scholar]
  24. Chou M. J., Lee T. H., Hatzakis A., Mandalaki T., McLane M. F., Essex M. Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs. J Infect Dis. 1988 Apr;157(4):805–811. doi: 10.1093/infdis/157.4.805. [DOI] [PubMed] [Google Scholar]
  25. Cianciolo G. J., Bogerd H., Snyderman R. Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation. Immunol Lett. 1988 Sep;19(1):7–13. doi: 10.1016/0165-2478(88)90112-5. [DOI] [PubMed] [Google Scholar]
  26. Coates R. A., Farewell V. T., Raboud J., Read S. E., Klein M., MacFadden D. K., Calzavara L. M., Johnson J. K., Fanning M. M., Shepherd F. A. Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. J Clin Epidemiol. 1992 Mar;45(3):245–253. doi: 10.1016/0895-4356(92)90084-z. [DOI] [PubMed] [Google Scholar]
  27. Coates R. A., Read S. E., Fanning M. M., Vellend H., Shepherd F. A., Johnson J. K. The relationship between 2-5A synthetase levels and persistent lymphadenopathy in homosexual men with antibodies to HTLV-III. Clin Invest Med. 1986;9(2):59–64. [PubMed] [Google Scholar]
  28. Cohen A. J., Philips T. M., Kessler C. M. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Feb;104(2):175–180. doi: 10.7326/0003-4819-104-2-175. [DOI] [PubMed] [Google Scholar]
  29. Cohen H., Mackie I. J., Anagnostopoulos N., Savage G. F., Machin S. J. Lupus anticoagulant, anticardiolipin antibodies, and human immunodeficiency virus in haemophilia. J Clin Pathol. 1989 Jun;42(6):629–633. doi: 10.1136/jcp.42.6.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Coombs R. W., Collier A. C., Allain J. P., Nikora B., Leuther M., Gjerset G. F., Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989 Dec 14;321(24):1626–1631. doi: 10.1056/NEJM198912143212402. [DOI] [PubMed] [Google Scholar]
  31. Cooper D. A., Gold J., Maclean P., Donovan B., Finlayson R., Barnes T. G., Michelmore H. M., Brooke P., Penny R. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1985 Mar 9;1(8428):537–540. doi: 10.1016/s0140-6736(85)91205-x. [DOI] [PubMed] [Google Scholar]
  32. De Paoli P., Carbone A., Battistin S., Crovatto M., Arreghini N., Santini G. Selective depletion of the OKT 4+ 4B4+ subset in lymph nodes from HIV+ patients. Immunol Lett. 1987 Oct;16(1):71–73. doi: 10.1016/0165-2478(87)90064-2. [DOI] [PubMed] [Google Scholar]
  33. De Wolf F., Roos M., Lange J. M., Houweling J. T., Coutinho R. A., van der Noordaa J., Schellekens P. T., Goudsmit J. Decline in CD4+ cell numbers reflects increase in HIV-1 replication. AIDS Res Hum Retroviruses. 1988 Dec;4(6):433–440. doi: 10.1089/aid.1988.4.433. [DOI] [PubMed] [Google Scholar]
  34. DeStefano E., Friedman R. M., Friedman-Kien A. E., Goedert J. J., Henriksen D., Preble O. T., Sonnabend J. A., Vilcek J. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis. 1982 Oct;146(4):451–459. doi: 10.1093/infdis/146.4.451. [DOI] [PubMed] [Google Scholar]
  35. Devash Y., Calvelli T. A., Wood D. G., Reagan K. J., Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci U S A. 1990 May;87(9):3445–3449. doi: 10.1073/pnas.87.9.3445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Elovaara I., Iivanainen M., Poutiainen E., Valle S. L., Weber T., Suni J., Lähdevirta J. CSF and serum beta-2-microglobulin in HIV infection related to neurological dysfunction. Acta Neurol Scand. 1989 Feb;79(2):81–87. doi: 10.1111/j.1600-0404.1989.tb03717.x. [DOI] [PubMed] [Google Scholar]
  37. Eyster M. E., Ballard J. O., Gail M. H., Drummond J. E., Goedert J. J. Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count. Ann Intern Med. 1989 Jun 15;110(12):963–969. doi: 10.7326/0003-4819-110-12-963. [DOI] [PubMed] [Google Scholar]
  38. Eyster M. E., Gail M. H., Ballard J. O., Al-Mondhiry H., Goedert J. J. Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med. 1987 Jul;107(1):1–6. doi: 10.7326/0003-4819-107-1-1. [DOI] [PubMed] [Google Scholar]
  39. Fahey J. L., Taylor J. M., Detels R., Hofmann B., Melmed R., Nishanian P., Giorgi J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990 Jan 18;322(3):166–172. doi: 10.1056/NEJM199001183220305. [DOI] [PubMed] [Google Scholar]
  40. Farzadegan H., Chmiel J. S., Odaka N., Ward L., Poggensee L., Saah A., Phair J. P. Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number, and AIDS-free time. J Infect Dis. 1992 Dec;166(6):1217–1222. doi: 10.1093/infdis/166.6.1217. [DOI] [PubMed] [Google Scholar]
  41. Fauci A. S., Macher A. M., Longo D. L., Lane H. C., Rook A. H., Masur H., Gelmann E. P. NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med. 1984 Jan;100(1):92–106. doi: 10.7326/0003-4819-100-1-92. [DOI] [PubMed] [Google Scholar]
  42. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  43. Fling J. A., Fischer J. R., Jr, Boswell R. N., Reid M. J. The relationship of serum IgA concentration to human immunodeficiency virus (HIV) infection: a cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force. J Allergy Clin Immunol. 1988 Dec;82(6):965–970. doi: 10.1016/0091-6749(88)90132-7. [DOI] [PubMed] [Google Scholar]
  44. Forman D. T. Beta-2 microglobulin--an immunogenetic marker of inflammatory and malignant origin. Ann Clin Lab Sci. 1982 Nov-Dec;12(6):447–452. [PubMed] [Google Scholar]
  45. Forster S. M., Osborne L. M., Cheingsong-Popov R., Kenny C., Burnell R., Jeffries D. J., Pinching A. J., Harris J. R., Weber J. N. Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection. AIDS. 1987 Dec;1(4):235–240. [PubMed] [Google Scholar]
  46. Franzetti F., Cavalli G., Foppa C. U., Amprimo M. C., Gaido P., Lazzarin A. Raised serum beta 2 microglobulin levels in different stages of human immunodeficiency virus infection. J Clin Lab Immunol. 1988 Nov;27(3):133–137. [PubMed] [Google Scholar]
  47. Fuchs D., Artner-Dworzak E., Hausen A., Reibnegger G., Werner E. R., Werner-Felmayer G., Dierich M. P., Wachter H. Urinary excretion of porphyrins is increased in patients with HIV-1 infection. AIDS. 1990 Apr;4(4):341–344. doi: 10.1097/00002030-199004000-00009. [DOI] [PubMed] [Google Scholar]
  48. Fuchs D., Banekovich M., Hausen A., Hutterer J., Reibnegger G., Werner E. R., Gschnait F. D., Dierich M. P., Wachter H. Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1. Clin Chem. 1988 Dec;34(12):2415–2417. [PubMed] [Google Scholar]
  49. Fuchs D., Chiodi F., Albert J., Asjö B., Hagberg L., Hausen A., Norkrans G., Reibnegger G., Werner E. R., Wachter H. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS. 1989 May;3(5):285–288. doi: 10.1097/00002030-198905000-00006. [DOI] [PubMed] [Google Scholar]
  50. Fuchs D., Hausen A., Reibnegger G., Werner E. R., Dierich M. P., Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988 May;9(5):150–155. doi: 10.1016/0167-5699(88)91203-0. [DOI] [PubMed] [Google Scholar]
  51. Fuchs D., Hausen A., Reibnegger G., Werner E. R., Dierich M. P., Wachter H. Neopterin as a marker in HIV infection. Clin Chem. 1988 Feb;34(2):466–467. [PubMed] [Google Scholar]
  52. Fuchs D., Spira T. J., Hausen A., Reibnegger G., Werner E. R., Felmayer G. W., Wachter H. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem. 1989 Aug;35(8):1746–1749. [PubMed] [Google Scholar]
  53. Gaines H., von Sydow M., Sönnerborg A., Albert J., Czajkowski J., Pehrson P. O., Chiodi F., Moberg L., Fenyö E. M., Asjö B. Antibody response in primary human immunodeficiency virus infection. Lancet. 1987 May 30;1(8544):1249–1253. doi: 10.1016/s0140-6736(87)92696-1. [DOI] [PubMed] [Google Scholar]
  54. Giorgi J. V., Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol. 1989 Jul;52(1):10–18. doi: 10.1016/0090-1229(89)90188-8. [DOI] [PubMed] [Google Scholar]
  55. Giorgi J. V., Nishanian P. G., Schmid I., Hultin L. E., Cheng H. L., Detels R. Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection. J Clin Immunol. 1987 Mar;7(2):140–150. doi: 10.1007/BF00916008. [DOI] [PubMed] [Google Scholar]
  56. Goedert J. J., Kessler C. M., Aledort L. M., Biggar R. J., Andes W. A., White G. C., 2nd, Drummond J. E., Vaidya K., Mann D. L., Eyster M. E. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989 Oct 26;321(17):1141–1148. doi: 10.1056/NEJM198910263211701. [DOI] [PubMed] [Google Scholar]
  57. Goedert J. J., Mendez H., Drummond J. E., Robert-Guroff M., Minkoff H. L., Holman S., Stevens R., Rubinstein A., Blattner W. A., Willoughby A. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet. 1989 Dec 9;2(8676):1351–1354. doi: 10.1016/s0140-6736(89)91965-x. [DOI] [PubMed] [Google Scholar]
  58. Grieco M. H., Reddy M. M., Kothari H. B., Lange M., Buimovici-Klein E., William D. Elevated beta 2-microglobulin and lysozyme levels in patients with acquired immune deficiency syndrome. Clin Immunol Immunopathol. 1984 Aug;32(2):174–184. doi: 10.1016/0090-1229(84)90119-3. [DOI] [PubMed] [Google Scholar]
  59. Griffin D. E., McArthur J. C., Cornblath D. R. Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease. J Neuroimmunol. 1990 Jul;28(2):97–109. doi: 10.1016/0165-5728(90)90024-h. [DOI] [PubMed] [Google Scholar]
  60. Gupta S., Licorish K. Circulating immune complexes in AIDS. N Engl J Med. 1984 Jun 7;310(23):1530–1531. doi: 10.1056/NEJM198406073102312. [DOI] [PubMed] [Google Scholar]
  61. Hafler D. A., Fox D. A., Benjamin D., Weiner H. L. Antigen reactive memory T cells are defined by Ta1. J Immunol. 1986 Jul 15;137(2):414–418. [PubMed] [Google Scholar]
  62. Hofmann B., Bygbjerg I., Dickmeiss E., Faber V., Frederiksen B., Gaub J., Gerstoft J., Jakobsen B. K., Jakobsen K. D., Lindhardt B. O. Prognostic value of immunologic abnormalities and HIV antigenemia in asymptomatic HIV-infected individuals: proposal of immunologic staging. Scand J Infect Dis. 1989;21(6):633–643. doi: 10.3109/00365548909021691. [DOI] [PubMed] [Google Scholar]
  63. Hofmann B., Nishanian P., Fahey J. L., Esmail I., Jackson A. L., Detels R., Cumberland W. Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change. Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 1):212–224. doi: 10.1016/s0090-1229(05)80025-x. [DOI] [PubMed] [Google Scholar]
  64. Hofmann B., Wang Y. X., Cumberland W. G., Detels R., Bozorgmehri M., Fahey J. L. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS. 1990 Mar;4(3):207–214. [PubMed] [Google Scholar]
  65. Honda M., Kitamura K., Matsuda K., Yokota Y., Yamamoto N., Mitsuyasu R., Chermann J. C., Tokunaga T. Soluble IL-2 receptor in AIDS. Correlation of its serum level with the classification of HIV-induced diseases and its characterization. J Immunol. 1989 Jun 15;142(12):4248–4255. [PubMed] [Google Scholar]
  66. Huber C., Batchelor J. R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984 Jul 1;160(1):310–316. doi: 10.1084/jem.160.1.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Huber C., Fuchs D., Hausen A., Margreiter R., Reibnegger G., Spielberger M., Wachter H. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol. 1983 Mar;130(3):1047–1050. [PubMed] [Google Scholar]
  68. Imberciadori G., Piersantelli N., Bo A., Calderisi S., Emanuelli F., Marchetto E., Penco G., Farinelli M., Arata L., Ribizzi G. Study of beta-2 microglobulin and neopterin in serum and cerebrospinal fluid of HIV-infected patients. Acta Neurol (Napoli) 1990 Feb;12(1):58–61. [PubMed] [Google Scholar]
  69. Intrator L., Oksenhendler E., Desforges L., Bierling P. Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura. Br J Haematol. 1988 Feb;68(2):269–270. doi: 10.1111/j.1365-2141.1988.tb06206.x. [DOI] [PubMed] [Google Scholar]
  70. Jackson J. B., Sannerud K. J., Balfour H. H., Jr Comparison of two serum HIV antigen assays for selection of asymptomatic antigenemic individuals into clinical trials. J Acquir Immune Defic Syndr. 1989;2(4):394–397. [PubMed] [Google Scholar]
  71. Jacobson M. A., Abrams D. I., Volberding P. A., Bacchetti P., Wilber J., Chaisson R. E., Crowe S., Howard W., Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun;159(6):1029–1036. doi: 10.1093/infdis/159.6.1029. [DOI] [PubMed] [Google Scholar]
  72. Jacobson M. A., Bacchetti P., Kolokathis A., Chaisson R. E., Szabo S., Polsky B., Valainis G. T., Mildvan D., Abrams D., Wilber J. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991 Jan 12;302(6768):73–78. doi: 10.1136/bmj.302.6768.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Jokela J., Flynn T., Henry K. Thrombotic thrombocytopenic purpura in a human immunodeficiency virus (HIV)-seropositive homosexual man. Am J Hematol. 1987 Jul;25(3):341–343. doi: 10.1002/ajh.2830250315. [DOI] [PubMed] [Google Scholar]
  74. Joller-Jemelka H. I., Joller P. W., Müller F., Schüpbach J., Grob P. J. Anti-HIV IgM antibody analysis during early manifestations of HIV infections. AIDS. 1987 May;1(1):45–47. [PubMed] [Google Scholar]
  75. Jones P. Zidovudine: experience at the Newcastle Haemophilia Centre. J Infect. 1989 Jan;18 (Suppl 1):53–58. doi: 10.1016/s0163-4453(89)80080-5. [DOI] [PubMed] [Google Scholar]
  76. Karlsson F. A., Groth T., Sege K., Wibell L., Peterson P. A. Turnover in humans of beta 2-microglobulin: the constant chain of HLA-antigens. Eur J Clin Invest. 1980 Aug;10(4):293–300. doi: 10.1111/j.1365-2362.1980.tb00036.x. [DOI] [PubMed] [Google Scholar]
  77. Karpatkin S. HIV-1-related thrombocytopenia. Hematol Oncol Clin North Am. 1990 Feb;4(1):193–218. [PubMed] [Google Scholar]
  78. Kiprov D. D., Anderson R. E., Morand P. R., Simpson D. M., Chermann J. C., Levy J. A., Ross A. R. Antilymphocyte antibodies and seropositivity for retroviruses in groups at high risk for AIDS. N Engl J Med. 1985 Jun 6;312(23):1517–1517. doi: 10.1056/NEJM198506063122312. [DOI] [PubMed] [Google Scholar]
  79. Kloster B. E., John P. A., Miller L. E., Rubin L. A., Nelson D. L., Blair D. C., Tomar R. H. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987 Dec;45(3):440–446. doi: 10.1016/0090-1229(87)90095-x. [DOI] [PubMed] [Google Scholar]
  80. Kofler H., Fuchs D., Hintner H., Wachter H., Fritsch P. Urinary neopterin: an early marker of HIV infection. Eur J Clin Microbiol. 1987 Dec;6(6):698–699. doi: 10.1007/BF02013081. [DOI] [PubMed] [Google Scholar]
  81. Koot M., Keet I. P., Vos A. H., de Goede R. E., Roos M. T., Coutinho R. A., Miedema F., Schellekens P. T., Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993 May 1;118(9):681–688. doi: 10.7326/0003-4819-118-9-199305010-00004. [DOI] [PubMed] [Google Scholar]
  82. Krowka J. F., Stites D. P., Moss A. R., Casavant C. H., Carlson J. R., Chermann J. C., Barre-Sinoussi F., Rodgers R. P., Bacchetti P., McHugh T. M. Interrelations of lymphocyte subset values, human immunodeficiency virus antibodies, and HIV antigen levels of homosexual males in San Francisco. Diagn Clin Immunol. 1988;5(6):381–387. [PubMed] [Google Scholar]
  83. Krämer A., Wiktor S. Z., Fuchs D., Milstien S., Gail M. H., Yellin F. J., Biggar R. J., Wachter H., Kaufman S., Blattner W. A. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1989;2(3):291–296. [PubMed] [Google Scholar]
  84. Lacey J. N., Forbes M. A., Waugh M. A., Cooper E. H., Hambling M. H. Serum beta 2-microglobulin and human immunodeficiency virus infection. AIDS. 1987 Jul;1(2):123–127. [PubMed] [Google Scholar]
  85. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  86. Lambin P., Desjobert H., Debbia M., Fine J. M., Muller J. Y. Serum neopterin and beta 2-microglobulin in anti-HIV positive blood donors. Lancet. 1986 Nov 22;2(8517):1216–1216. doi: 10.1016/s0140-6736(86)92219-1. [DOI] [PubMed] [Google Scholar]
  87. Lambin P., Lefrere J. J., Doinel C., Fine J. M., Salmon D., Salmon C. Neopterin and beta 2-microglobulin in serum of HIV-seropositive subjects during a two-year follow-up. Clin Chem. 1988 Jun;34(6):1367–1368. [PubMed] [Google Scholar]
  88. Landay A., Ohlsson-Wilhelm B., Giorgi J. V. Application of flow cytometry to the study of HIV infection. AIDS. 1990 Jun;4(6):479–497. doi: 10.1097/00002030-199006000-00001. [DOI] [PubMed] [Google Scholar]
  89. Lane H. C., Depper J. M., Greene W. C., Whalen G., Waldmann T. A., Fauci A. S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 1985 Jul 11;313(2):79–84. doi: 10.1056/NEJM198507113130204. [DOI] [PubMed] [Google Scholar]
  90. Lang W., Perkins H., Anderson R. E., Royce R., Jewell N., Winkelstein W., Jr Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr. 1989;2(1):63–69. [PubMed] [Google Scholar]
  91. Lange J. M., Paul D. A., Huisman H. G., de Wolf F., van den Berg H., Coutinho R. A., Danner S. A., van der Noordaa J., Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1459–1462. doi: 10.1136/bmj.293.6560.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Lange J. M., de Wolf F., Krone W. J., Danner S. A., Coutinho R. A., Goudsmit J. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS. 1987 Sep;1(3):155–159. [PubMed] [Google Scholar]
  93. Lange J., Vahlne A., Dekker J., de Wolf F., Goudsmit J. Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS. AIDS. 1989 Jun;3(6):402–403. doi: 10.1097/00002030-198906000-00013. [DOI] [PubMed] [Google Scholar]
  94. Lau A. S., Der S. D., Read S. E., Williams B. R. Regulation of tumor necrosis factor receptor expression by acid-labile interferon-alpha from AIDS sera. AIDS Res Hum Retroviruses. 1991 Jun;7(6):545–552. doi: 10.1089/aid.1991.7.545. [DOI] [PubMed] [Google Scholar]
  95. Lee C. A., Phillips A., Elford J., Miller E. J., Bofill M., Griffiths P. D., Kernoff P. B. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol. 1989 Oct;73(2):228–234. doi: 10.1111/j.1365-2141.1989.tb00257.x. [DOI] [PubMed] [Google Scholar]
  96. Lähdevirta J., Maury C. P., Teppo A. M., Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Sep;85(3):289–291. doi: 10.1016/0002-9343(88)90576-1. [DOI] [PubMed] [Google Scholar]
  97. Masur H., Ognibene F. P., Yarchoan R., Shelhamer J. H., Baird B. F., Travis W., Suffredini A. F., Deyton L., Kovacs J. A., Falloon J. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Aug 1;111(3):223–231. doi: 10.7326/0003-4819-111-3-223. [DOI] [PubMed] [Google Scholar]
  98. McDougal J. S., Hubbard M., Nicholson J. K., Jones B. M., Holman R. C., Roberts J., Fishbein D. B., Jaffe H. W., Kaplan J. E., Spira T. J. Immune complexes in the acquired immunodeficiency syndrome (AIDS): relationship to disease manifestation, risk group, and immunologic defect. J Clin Immunol. 1985 Mar;5(2):130–138. doi: 10.1007/BF00915011. [DOI] [PubMed] [Google Scholar]
  99. McDougal J. S., Kennedy M. S., Sligh J. M., Cort S. P., Mawle A., Nicholson J. K. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science. 1986 Jan 24;231(4736):382–385. doi: 10.1126/science.3001934. [DOI] [PubMed] [Google Scholar]
  100. Melmed R. N., Taylor J. M., Detels R., Bozorgmehri M., Fahey J. L. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr. 1989;2(1):70–76. [PubMed] [Google Scholar]
  101. Merigan T. C. You can teach an old dog new tricks. How AIDS trials are pioneering new strategies. N Engl J Med. 1990 Nov 8;323(19):1341–1343. doi: 10.1056/NEJM199011083231911. [DOI] [PubMed] [Google Scholar]
  102. Ming W. J., Bersani L., Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 1987 Mar 1;138(5):1469–1474. [PubMed] [Google Scholar]
  103. Mintz M., Rapaport R., Oleske J. M., Connor E. M., Koenigsberger M. R., Denny T., Epstein L. G. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. Am J Dis Child. 1989 Jul;143(7):771–774. doi: 10.1001/archpedi.1989.02150190021012. [DOI] [PubMed] [Google Scholar]
  104. Mizuma H., Litwin S., Zolla-Pazner S. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin Exp Immunol. 1988 Mar;71(3):410–416. [PMC free article] [PubMed] [Google Scholar]
  105. Morimoto C., Letvin N. L., Boyd A. W., Hagan M., Brown H. M., Kornacki M. M., Schlossman S. F. The isolation and characterization of the human helper inducer T cell subset. J Immunol. 1985 Jun;134(6):3762–3769. [PubMed] [Google Scholar]
  106. Morimoto C., Torimoto Y., Levinson G., Rudd C. E., Schrieber M., Dang N. H., Letvin N. L., Schlossman S. F. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol. 1989 Dec 1;143(11):3430–3439. [PubMed] [Google Scholar]
  107. Morris L., Distenfeld A., Amorosi E., Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med. 1982 Jun;96(6 Pt 1):714–717. doi: 10.7326/0003-4819-96-6-714. [DOI] [PubMed] [Google Scholar]
  108. Moss A. R., Bacchetti P., Osmond D., Krampf W., Chaisson R. E., Stites D., Wilber J., Allain J. P., Carlson J. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988 Mar 12;296(6624):745–750. doi: 10.1136/bmj.296.6624.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Mulder J. W., Krijnen P., Goudsmit J., Schattenkerk J. K., Reiss P., Lange J. M. HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients. Genitourin Med. 1990 Jun;66(3):138–141. doi: 10.1136/sti.66.3.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Nicholson J. K., Jones B. M., Echenberg D. F., Spira T. J., McDougal J. S. Phenotypic distribution of T cells of patients who have subsequently developed AIDS. Clin Immunol Immunopathol. 1987 Apr;43(1):82–87. doi: 10.1016/0090-1229(87)90159-0. [DOI] [PubMed] [Google Scholar]
  111. Nicholson J. K., Jones B. M. Lymphocyte immunophenotyping at the Centers for Disease Control: the program and special studies. Clin Immunol Immunopathol. 1989 Jul;52(1):61–67. doi: 10.1016/0090-1229(89)90193-1. [DOI] [PubMed] [Google Scholar]
  112. Niederwieser A., Joller P., Seger R., Blau N., Prader A., Bettex J. D., Lüthy R., Hirschel B., Schaedelin J., Vetter U. Neopterin in AIDs, other immunodeficiencies, and bacterial and viral infections. Klin Wochenschr. 1986 Apr 1;64(7):333–337. doi: 10.1007/BF01711954. [DOI] [PubMed] [Google Scholar]
  113. Niederwieser D., Huber C., Gratwohl A., Bannert P., Fuchs D., Hausen A., Reibnegger G., Speck B., Wachter H. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation. 1984 Nov;38(5):497–500. doi: 10.1097/00007890-198411000-00011. [DOI] [PubMed] [Google Scholar]
  114. Nishanian P., Hofmann B., Wang Y., Jackson A. L., Detels R., Fahey J. L. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. AIDS. 1991 Jul;5(7):805–812. doi: 10.1097/00002030-199107000-00003. [DOI] [PubMed] [Google Scholar]
  115. Odell T. W., Green J. A. Prolonged zidovudine therapy: confounded by Pneumocystis carinii prophylaxis? JAMA. 1990 Mar 23;263(12):1635–1636. [PubMed] [Google Scholar]
  116. Orgad S., Malone G., Zaizov R., Marinowitz U., McLane M. F., Umiel T., Cohen I. J., Vogel R., Cohen-Avishai O., Ramot B. Antibodies to HIV in Israeli hemophiliacs: relationship between serological profile and disease development. AIDS Res Hum Retroviruses. 1987 Fall;3(3):323–332. doi: 10.1089/aid.1987.3.323. [DOI] [PubMed] [Google Scholar]
  117. Orholm M., Pedersen C., Mathiesen L., Dowd P., Nielsen J. O. Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study. AIDS. 1989 Feb;3(2):97–100. doi: 10.1097/00002030-198902000-00008. [DOI] [PubMed] [Google Scholar]
  118. Ozturk G. E., Kohler P. F., Horsburgh C. R., Jr, Kirkpatrick C. H. The significance of antilymphocyte antibodies in patients with acquired immune deficiency syndrome (AIDS) and their sexual partners. J Clin Immunol. 1987 Mar;7(2):130–139. doi: 10.1007/BF00916007. [DOI] [PubMed] [Google Scholar]
  119. Panzer S., Stain C., Hartl H., Dudczak R., Lechner K. Anticardiolipin antibodies are elevated in HIV-1 infected haemophiliacs but do not predict for disease progression. Thromb Haemost. 1989 Feb 28;61(1):81–85. [PubMed] [Google Scholar]
  120. Parkin J. M., Helbert M., Hughes C. L., Pinching A. J. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS. 1989 Jan;3(1):37–39. [PubMed] [Google Scholar]
  121. Paul D. A., Falk L. A., Kessler H. A., Chase R. M., Blaauw B., Chudwin D. S., Landay A. L. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol. 1987 Aug;22(4):357–363. doi: 10.1002/jmv.1890220408. [DOI] [PubMed] [Google Scholar]
  122. Perkocha L. A., Rodgers G. M. Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations. Am J Hematol. 1988 Oct;29(2):94–105. doi: 10.1002/ajh.2830290207. [DOI] [PubMed] [Google Scholar]
  123. Phillips A., Lee C. A., Elford J., Janossy G., Bofill M., Timms A., Kernoff P. B. Prediction of progression to AIDS by analysis of CD4 lymphocyte counts in a haemophilic cohort. AIDS. 1989 Nov;3(11):737–741. doi: 10.1097/00002030-198911000-00008. [DOI] [PubMed] [Google Scholar]
  124. Polis M. A., Masur H. Predicting the progression to AIDS. Am J Med. 1990 Dec;89(6):701–705. doi: 10.1016/0002-9343(90)90209-v. [DOI] [PubMed] [Google Scholar]
  125. Prince H. E., Jensen E. R. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr. 1991;4(12):1227–1232. [PubMed] [Google Scholar]
  126. Prince H. E., Kleinman S., Czaplicki C., John J., Williams A. E. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr. 1990;3(5):525–530. [PubMed] [Google Scholar]
  127. Prince H. E., Kleinman S., Williams A. E. Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. J Immunol. 1988 Feb 15;140(4):1139–1141. [PubMed] [Google Scholar]
  128. Ragni M. V., O'Brien T. A., Reed D., Spero J. A., Lewis J. H. Prognostic importance of antibodies to human immunodeficiency virus by recombinant immunoassay and Western blot techniques in HIV antibody-positive hemophiliacs. AIDS Res Hum Retroviruses. 1988 Jun;4(3):223–231. doi: 10.1089/aid.1988.4.223. [DOI] [PubMed] [Google Scholar]
  129. Ranki A., Järvinen K., Valle S. L., Nurmilaakso P., Krohn K. Antibodies to recombinant HIV-1 nef protein detected in HIV-1 infection as well as in nonrisk individuals. J Acquir Immune Defic Syndr. 1990;3(4):348–355. [PubMed] [Google Scholar]
  130. Reddy M. M., Grieco M. H. Neopterin and alpha and beta interleukin-1 levels in sera of patients with human immunodeficiency virus infection. J Clin Microbiol. 1989 Sep;27(9):1919–1923. doi: 10.1128/jcm.27.9.1919-1923.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Reddy M. M., Grieco M. H. Neopterin and alpha and beta interleukin-1 levels in sera of patients with human immunodeficiency virus infection. J Clin Microbiol. 1989 Sep;27(9):1919–1923. doi: 10.1128/jcm.27.9.1919-1923.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Reddy M. M., Sorrell S. J., Lange M., Grieco M. H. Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations. J Acquir Immune Defic Syndr. 1988;1(5):436–440. [PubMed] [Google Scholar]
  133. Reiss P., de Ronde A., Lange J. M., de Wolf F., Dekker J., Debouck C., Goudsmit J. Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression. AIDS. 1989 Apr;3(4):227–233. doi: 10.1097/00002030-198904000-00006. [DOI] [PubMed] [Google Scholar]
  134. Robb R. J., Munck A., Smith K. A. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med. 1981 Nov 1;154(5):1455–1474. doi: 10.1084/jem.154.5.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Rollag H., Evensen S. A., Frøland S. S., Glomstein A. The significance of HIV antigen and HIV antibodies specific against envelope and core proteins in serum of HIV-infected hemophiliacs. Eur J Haematol. 1987 Oct;39(4):353–355. doi: 10.1111/j.1600-0609.1987.tb00782.x. [DOI] [PubMed] [Google Scholar]
  136. Roux-Lombard P., Modoux C., Cruchaud A., Dayer J. M. Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol. 1989 Mar;50(3):374–384. doi: 10.1016/0090-1229(89)90144-x. [DOI] [PubMed] [Google Scholar]
  137. Roy S., Morrow W. J., Christian C., Khayam-Bashi H., Busch M. P., McCarthy R., Rodgers R. P., Vyas G. N. Persistent immune complexes and abnormal CD4/CD8 ratios in HIV infection. J Acquir Immune Defic Syndr. 1990;3(2):134–138. [PubMed] [Google Scholar]
  138. Ruedy J., Schechter M., Montaner J. S. Zidovudine for early human immunodeficiency virus (HIV) infection: who, when, and how? Ann Intern Med. 1990 May 15;112(10):721–723. doi: 10.7326/0003-4819-112-10-721. [DOI] [PubMed] [Google Scholar]
  139. Rugman F. P., Mannion P. T., Hay C. R., Bolton-Maggs P., Roberts D., Mutton K. J. Cytomegalovirus, serum beta 2 microglobulin, and progression to AIDS in HIV-seropositive haemophiliacs. Lancet. 1989 Sep 9;2(8663):631–631. doi: 10.1016/s0140-6736(89)90762-9. [DOI] [PubMed] [Google Scholar]
  140. Santelli G., Melillo G., Marfella A., Napolitano M., D'Alessio V., Satriano R. A., Beth-Giraldo E., Giraldo G., Perna M., Castello G. Urinary neopterin and immunological features in patients with Kaposi's sarcoma. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1391–1396. doi: 10.1016/0277-5379(88)90327-6. [DOI] [PubMed] [Google Scholar]
  141. Savona S., Nardi M. A., Lennette E. T., Karpatkin S. Thrombocytopenic purpura in narcotics addicts. Ann Intern Med. 1985 Jun;102(6):737–741. doi: 10.7326/0003-4819-102-6-737. [DOI] [PubMed] [Google Scholar]
  142. Scadden D. T., Zon L. I., Groopman J. E. Pathophysiology and management of HIV-associated hematologic disorders. Blood. 1989 Oct;74(5):1455–1463. [PubMed] [Google Scholar]
  143. Schechter M. T., Boyko W. J., Craib K. J., McLeod A., Willoughby B., Douglas B., Constance P., O'Shaughnessey M. Effects of long-term seropositivity to human immunodeficiency virus in a cohort of homosexual men. AIDS. 1987 Jul;1(2):77–82. [PubMed] [Google Scholar]
  144. Schechter M. T., Craib K. J., Le T. N., Willoughby B., Douglas B., Sestak P., Montaner J. S., Weaver M. S., Elmslie K. D., O'Shaughnessy M. V. Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS. 1989 Jun;3(6):347–353. doi: 10.1097/00002030-198906000-00002. [DOI] [PubMed] [Google Scholar]
  145. Schulof R. S., Parenti D. M., Simon G. L., Paxton H., Meyer W. A., 3rd, Schlesselman S. B., Courtless J., LeLacheur S., Sztein M. B. Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men. J Acquir Immune Defic Syndr. 1990;3(5):485–492. [PubMed] [Google Scholar]
  146. Schüpbach J., Haller O., Vogt M., Lüthy R., Joller H., Oelz O., Popovic M., Sarngadharan M. G., Gallo R. C. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med. 1985 Jan 31;312(5):265–270. doi: 10.1056/NEJM198501313120502. [DOI] [PubMed] [Google Scholar]
  147. Sekigawa I., Groopmen J. E., Allan J. D., Ikeuchi K., Biberfield G., Takatsuki K., Byrn R. A. Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection. Clin Immunol Immunopathol. 1991 Jan;58(1):145–153. doi: 10.1016/0090-1229(91)90156-5. [DOI] [PubMed] [Google Scholar]
  148. Seligmann M., Chess L., Fahey J. L., Fauci A. S., Lachmann P. J., L'Age-Stehr J., Ngu J., Pinching A. J., Rosen F. S., Spira T. J. AIDS--an immunologic reevaluation. N Engl J Med. 1984 Nov 15;311(20):1286–1292. doi: 10.1056/NEJM198411153112005. [DOI] [PubMed] [Google Scholar]
  149. Sheppard H. W., Ascher M. S., McRae B., Anderson R. E., Lang W., Allain J. P. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr. 1991;4(7):704–712. [PubMed] [Google Scholar]
  150. Sher R. Beta 2-microglobulin levels in homosexual men in Johannesburg, South Africa. AIDS Res. 1983 1984;1(4):271–274. doi: 10.1089/aid.1.1983.1.271. [DOI] [PubMed] [Google Scholar]
  151. Sherry B., Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol. 1988 Oct;107(4):1269–1277. doi: 10.1083/jcb.107.4.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Spector S. A., Kennedy C., McCutchan J. A., Bozzette S. A., Straube R. G., Connor J. D., Richman D. D. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J Infect Dis. 1989 May;159(5):822–828. doi: 10.1093/infdis/159.5.822. [DOI] [PubMed] [Google Scholar]
  153. Steinberg J. P., Spear J. B., Murphy R. L., Wallemark C. B., Benson C. A., Kessler H. A., Pottage J. C., Jr, Phair J. P. Predictors of outcome in AIDS patients receiving zidovudine. J Acquir Immune Defic Syndr. 1989;2(3):229–234. [PubMed] [Google Scholar]
  154. Stites D. P., Moss A. R., Bacchetti P., Osmond D., McHugh T. M., Wang Y. J., Hebert S., Colfer B. Lymphocyte subset analysis to predict progression to AIDS in a cohort of homosexual men in San Francisco. Clin Immunol Immunopathol. 1989 Jul;52(1):96–103. doi: 10.1016/0090-1229(89)90196-7. [DOI] [PubMed] [Google Scholar]
  155. Stricker R. B., Abrams D. I., Corash L., Shuman M. A. Target platelet antigen in homosexual men with immune thrombocytopenia. N Engl J Med. 1985 Nov 28;313(22):1375–1380. doi: 10.1056/NEJM198511283132202. [DOI] [PubMed] [Google Scholar]
  156. Stricker R. B., McHugh T. M., Moody D. J., Morrow W. J., Stites D. P., Shuman M. A., Levy J. A. An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells. 1987 Jun 25-Jul 1Nature. 327(6124):710–713. doi: 10.1038/327710a0. [DOI] [PubMed] [Google Scholar]
  157. Sönnerborg A. B., von Stedingk L. V., Hansson L. O., Strannegård O. O. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS. 1989 May;3(5):277–283. doi: 10.1097/00002030-198905000-00005. [DOI] [PubMed] [Google Scholar]
  158. Taylor J. M., Fahey J. L., Detels R., Giorgi J. V. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr. 1989;2(2):114–124. [PubMed] [Google Scholar]
  159. Teitel J. M., Freedman J. J., Garvey M. B., Kardish M. Two-year evaluation of clinical and laboratory variables of immune function in 117 hemophiliacs seropositive or seronegative for HIV-1. Am J Hematol. 1989 Dec;32(4):262–272. doi: 10.1002/ajh.2830320406. [DOI] [PubMed] [Google Scholar]
  160. Teshigawara K., Wang H. M., Kato K., Smith K. A. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med. 1987 Jan 1;165(1):223–238. doi: 10.1084/jem.165.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Thiriart C., Goudsmit J., Schellekens P., Barin F., Zagury D., De Wilde M., Bruck C. Antibodies to soluble CD4 in HIV-1-infected individuals. AIDS. 1988 Oct;2(5):345–351. doi: 10.1097/00002030-198810000-00003. [DOI] [PubMed] [Google Scholar]
  162. Tomkinson B. E., Brown M. C., Ip S. H., Carrabis S., Sullivan J. L. Soluble CD8 during T cell activation. J Immunol. 1989 Apr 1;142(7):2230–2236. [PubMed] [Google Scholar]
  163. Tomsová Z., Jůzová Z. Jednoduché chromatografické stanovení neopterinu-markeru imunopatií. Cas Lek Cesk. 1989 Jan 6;128(2):59–61. [PubMed] [Google Scholar]
  164. Ugen K. E., Goedert J. J., Boyer J., Refaeli Y., Frank I., Williams W. V., Willoughby A., Landesman S., Mendez H., Rubinstein A. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest. 1992 Jun;89(6):1923–1930. doi: 10.1172/JCI115798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
  166. Vuillier F., Lapresle C., Dighiero G. Comparative analysis of CD4-4B4 and CD4-2H4 lymphocyte subpopulations in HIV negative homosexual, HIV seropositive and healthy subjects. Clin Exp Immunol. 1988 Jan;71(1):8–12. [PMC free article] [PubMed] [Google Scholar]
  167. Walsh C. M., Nardi M. A., Karpatkin S. On the mechanism of thrombocytopenic purpura in sexually active homosexual men. N Engl J Med. 1984 Sep 6;311(10):635–639. doi: 10.1056/NEJM198409063111004. [DOI] [PubMed] [Google Scholar]
  168. Werner E. R., Bichler A., Daxenbichler G., Fuchs D., Fuith L. C., Hausen A., Hetzel H., Reibnegger G., Wachter H. Determination of neopterin in serum and urine. Clin Chem. 1987 Jan;33(1):62–66. [PubMed] [Google Scholar]
  169. Wilks D., Walker L. C., Habeshaw J. A., Youle M., Gazzard B., Dalgleish A. G. Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive people. AIDS. 1990 Feb;4(2):113–118. doi: 10.1097/00002030-199002000-00003. [DOI] [PubMed] [Google Scholar]
  170. Witkin S. S., Bongiovanni A. M., Yu I. R., Goldstein M., Wallace J., Sonnabend J. Humoral immune responses in healthy heterosexual, homosexual and vasectomized men and in homosexual men with the acquired immune deficiency syndrome. AIDS Res. 1983 1984;1(1):31–44. doi: 10.1089/aid.1.1983.1.31. [DOI] [PubMed] [Google Scholar]
  171. Wright S. C., Jewett A., Mitsuyasu R., Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol. 1988 Jul 1;141(1):99–104. [PubMed] [Google Scholar]
  172. Yagi M. J., Chu F. N., Jiang J. D., Wallace J., Mason P., Liu Y., Carafa J., Bekesi J. G. Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol. 1992 May;63(2):126–134. doi: 10.1016/0090-1229(92)90004-8. [DOI] [PubMed] [Google Scholar]
  173. Yu J. R., Lennette E. T., Karpatkin S. Anti-F(ab')2 antibodies in thrombocytopenic patients at risk for acquired immunodeficiency syndrome. J Clin Invest. 1986 Jun;77(6):1756–1761. doi: 10.1172/JCI112498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Zolla-Pazner S., William D., El-Sadr W., Marmor M., Stahl R. Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome. JAMA. 1984 Jun 8;251(22):2951–2955. [PubMed] [Google Scholar]
  175. de Wit R., Bakker P. J., Reiss P., Hoek F. J., Lange J. M., Goudsmit J., Veenhof K. H. Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma. AIDS. 1990 May;4(5):459–462. doi: 10.1097/00002030-199005000-00013. [DOI] [PubMed] [Google Scholar]
  176. de Wolf F., Lange J. M., Houweling J. T., Coutinho R. A., Schellekens P. T., van der Noordaa J., Goudsmit J. Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis. 1988 Sep;158(3):615–622. doi: 10.1093/infdis/158.3.615. [DOI] [PubMed] [Google Scholar]
  177. dos Santos J. I., Castro B. G. Comparison of enzyme-linked immunosorbent assays and alternative tests for the detection of HIV antibodies in Brazilian sera. AIDS. 1989 Aug;3(8):544–545. doi: 10.1097/00002030-198908000-00011. [DOI] [PubMed] [Google Scholar]
  178. dos Santos J. I., Fernandez J. C., Galváo-Castro B. Specificity of HIV antigen capture assays. AIDS. 1989 Aug;3(8):545–545. doi: 10.1097/00002030-198908000-00012. [DOI] [PubMed] [Google Scholar]
  179. el-Sadr W., Marmor M., Zolla-Pazner S., Stahl R. E., Lyden R., William D., D'Onofrio S., Weiss S. H., Saxinger W. C. Four-year prospective study of homosexual men: correlation of immunologic abnormalities, clinical status, and serology to human immunodeficiency virus. J Infect Dis. 1987 Apr;155(4):789–793. doi: 10.1093/infdis/155.4.789. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES